A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The researcher are doing this study to find out whether benralizumab is effective at
preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin
rash is a common side effect of alpelisib. Researchers think adding benralizumab to the
standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.